Mar 5 |
Rigel Pharmaceuticals GAAP EPS of $0.00 beats by $0.02, revenue of $35.8M beats by $2.39M
|
Mar 5 |
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
Mar 5 |
Earnings Scheduled For March 5, 2024
|
Mar 4 |
Rigel Pharmaceuticals Q4 2023 Earnings Preview
|
Feb 28 |
OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock?
|
Feb 27 |
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update
|
Feb 26 |
Rigel Pharmaceuticals: Gavreto Deal Expands Growth Prospects
|
Feb 23 |
Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report
|
Feb 22 |
Rigel Pharmaceuticals acquires U.S. rights to Gavreto
|
Feb 22 |
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
|